Pfizer Inc. — 2011 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2011. This is an annual filing, not a standalone fourth-quarter report. The filing incorporates the detailed financial statements and MD&A by reference; the supplied text does not provide a clear value for consolidated revenue, net income, cash flow, debt, or liquidity balances.
Business context and financial highlights
- Pfizer is a global biopharmaceutical company with five operating segments. Its 2011 results include approximately 11 months of King’s U.S. operations and 10 months of King’s international operations following the acquisition.
- Biopharmaceutical revenue was $57.7 billion, down 1% from 2010. Loss of exclusivity and related declines in several products were partly offset by Lyrica, the Prevnar/Prevenar franchise, Enbrel, legacy King products, and favorable foreign exchange.
- U.S. biopharmaceutical revenue fell 9%; international biopharmaceutical revenue rose 5%, including a favorable 6% foreign-exchange effect. International operations generated $40.5 billion, or 60% of total revenue.
- Reported 2011 revenue for Animal Health was approximately $4.2 billion, up 17%; Consumer Healthcare was $3.1 billion, up 10%; and Nutrition was $2.1 billion, up 15%.
- Research and development expense was $9.1 billion, versus $9.4 billion in 2010 and $7.8 billion in 2009. Pfizer reported 262 R&D projects, including 22 Phase III programs, at year-end.
- Lipitor sales were approximately $9.6 billion, about 14% of total 2011 revenue. The filing says 12 biopharmaceutical products each generated more than $1 billion in direct product revenue and together represented 56% of biopharmaceutical revenue.
- Pfizer sold Capsugel for approximately $2.4 billion in cash in August 2011. It acquired King for approximately $3.6 billion in total cash consideration, including the tender offer and purchase of remaining shares.
- In the fourth quarter, Pfizer repurchased approximately 163.0 million shares at an average price of $19.70. The company authorized a further $10 billion repurchase plan in December and expected to repurchase approximately $5 billion of shares in 2012.
Material changes versus the prior comparable period
- Biopharmaceutical revenue declined 1% year over year, with operational revenue declines of $4.7 billion across specified products affected by loss of exclusivity and lower Aricept alliance revenue; the ACA reduced revenue by $359 million.
- King’s products contributed approximately $950 million to biopharmaceutical revenue and $329 million to Animal Health revenue. The King acquisition makes the year-over-year comparison less directly comparable.
- Animal Health, Consumer Healthcare, and Nutrition each reported revenue growth, supported by operational growth and, to varying degrees, foreign exchange and acquired products.
- Pfizer changed its segment structure from two operating segments to five. It also sold Capsugel and began exploring strategic alternatives for Animal Health and Nutrition.
Outlook, risks, contingencies, and unusual items
- Management expected Lipitor revenue in 2012 to be substantially below 2011 levels after U.S. exclusivity ended in November 2011 and further European losses of exclusivity. Geodon was expected to lose U.S. exclusivity in March 2012.
- The company expected significant R&D expense reductions from reprioritization and footprint changes, alongside significant related costs. Specific 2012 guidance figures are not present in the supplied filing text.
- Pfizer expected to announce strategic decisions for Animal Health and Nutrition in 2012, with any separation anticipated between July 2012 and July 2013.
- Key risks include generic and biosimilar competition; patent challenges and product concentration; pricing, reimbursement and healthcare regulation; product safety and regulatory outcomes; R&D attrition; foreign exchange; manufacturing and supply disruption; and litigation and government investigations.
- Prevnar 13’s adult uptake could be affected by the U.S. advisory committee’s decision to defer a routine-use recommendation pending further evidence. The CAPiTA trial was expected to complete in 2013.
- Pfizer stopped distributing Embeda in February 2011 and initiated a voluntary recall in March because of a product stability issue. The filing also identifies ongoing legal proceedings and environmental remediation obligations; the supplied text does not give a complete quantified estimate of potential exposure.
- Management stated that challenging economic conditions had not materially affected liquidity and that operating cash flows, financial assets, capital-market access, and credit facilities supported foreseeable liquidity needs. Balance-sheet amounts are not included in the supplied text.
Important facts for investors to verify
- Review the incorporated 2011 Financial Report for consolidated revenue, earnings, margins, operating cash flow, capital expenditures, cash and investments, debt maturities, and liquidity measures.
- Assess the timing and magnitude of post-Lipitor revenue and earnings declines, and the contribution of acquired King products and foreign exchange to reported growth.
- Check the detailed 2012 guidance, restructuring charges, and expected savings from R&D and productivity initiatives.
- Review the notes on litigation, patent challenges, contingencies, and any quantified reserves or reasonably possible losses.
- Track the strategic review of Animal Health and Nutrition, progress on the adult Prevnar 13 evidence, and key pipeline approvals and clinical milestones.